Towards Healthcare
Hematology Analyzers Market Size Climbs USD 4.33 Billion in 2025

Hematology Analyzers Market 2025 Drives by AI Integration, CBC Dominance & POCT Expansion

According to market projections, the global hematology analyzers market, valued at USD 4.08 billion in 2024, is anticipated to reach USD 7.28 billion by 2034, growing at a CAGR of 5.97% over the next decade. Majorly impacting factors like rising prevalence of blood disorders such as anaemia, thalassemia, leukemia, and progressing innovations in pharmacogenomics, stem cell research are driving the market growth. Whereas, North America was dominant in the hematology analyzers market due to high diagnostic volumes, chronic disease screening, and centralized lab chain

Category: Laboratory Equipment Insight Code: 5838 Format: PDF / PPT / Excel

Hematology Analyzers Market Size, Segment Analysis and Key Players

The global hematology analyzers market size is calculated at US$ 4.08 in 2024, grew to US$ 4.33 billion in 2025, and is projected to reach around US$ 7.28 billion by 2034. The market is expanding at a CAGR of 5.97% between 2025 and 2034.

Accelerating the growth of the global hematology analyzers market is fueled by increasing cases of blood conditions, including majorly anemia, blood cancers, coagulation disorders, and stem cell issues, along with the increased adoption of advanced diagnostic tools in hospitals and laboratories. These analyzers will provide information related to complete blood count, WBC, and RBC results. Moreover, around the world, the growing adoption of automated high-throughput analyzers, integration with AI/ML, and point-of-care testing (POCT), as well as oncology diagnostics, and preventive health screenings, are boosting the market growth.

Hematology Analyzers Market Size 2024 - 2034

Key Takeaways

  • Hematology analyzers market to cross USD 4.08 billion in 2024.
  • Market projected at USD 7.28 billion by 2034.
  • CAGR of 5.97% expected in between 2025 to 2034.
  • North America led the market with approximately 41% revenue share in 2024.
  • Asia Pacific is expected to grow at the fastest CAGR in the upcoming years.
  • By product type, the 5-part differential hematology analyzers segment held a ~51% share of the global hematology analyzers market in 2024.
  • By product type, the 6-part and above/high-end analyzers segment is expected to be the fastest-growing during 2025-2034.
  • Shape, PictureBy technology, the flow cytometry-based analyzers segment was dominant (~46%) in the market in 2024. 
  • Shape, PictureBy technology, the artificial intelligence & machine learning integration segment is expected to expand rapidly over the forecast period.
  • By application, the complete blood count (CBC) segment held the largest revenue share of nearly 58% in 2024.
  • By application, the coagulation & platelet studies segment is expected to register the fastest growth in the predicted timeframes.
  • By end user, the hospitals segment dominated with a ~42% share of the global hematology analyzers market in 2024.
  • By end user, the ambulatory surgical centers & physician offices segment is expected to be the fastest-growing during the 2025-2034 period.
  • Shape, PictureBy modality, the standalone hematology analyzers segment led the market in 2024. 
  • Shape, PictureBy modality, the integrated systems with immunoassay/chemistry platforms segment is expected to grow at a rapid CAGR in the upcoming years. 

Key Metrics and Overview

Metric Details
Market Size in 2025 USD 4.33 Billion
Projected Market Size in 2034 USD 7.28 Billion
CAGR (2025 - 2034) 5.97%
Leading Region North America share by 41%
Market Segmentation By Product Type, By Technology, By Application, By End User, By Modality, By Region
Top Key Players Sysmex Corporation, Beckman Coulter (Danaher Corporation), Abbott Laboratories, Siemens Healthineers, Horiba Ltd., Mindray Medical International Limited, Bio-Rad Laboratories, Inc., Roche Diagnostics, Boule Diagnostics AB, Diatron MI Zrt. (Stratec Biomedical), Nihon Kohden Corporation, Ortho Clinical Diagnostics, Drucker Diagnostics, PixCell Medical Technologies, Dymind Biotechnology Co., Ltd., Heska Corporation (veterinary segment), Agappe Diagnostics, Dirui Industrial Co., Ltd., Erba Mannheim (Transasia Bio-Medicals Ltd.), Thermo Fisher Scientific (hematology reagents & kits)

Market Overview

The hematology analyzers market includes diagnostic equipment used to analyze blood samples and generate complete blood counts (CBC) and other hematological parameters. These devices are essential in clinical laboratories, hospitals, and research settings for diagnosing conditions such as anemia, infections, blood cancers, and coagulation disorders. Technological advancements, including automated high-throughput analyzers, integration with AI/ML, and point-of-care testing (POCT), are driving market growth. The increasing demand from aging populations, oncology diagnostics, and preventive health screenings also contributes to the market’s expansion.

  • In December 2024, Axonia Medical, a leading provider of lab equipment, exclusively partnered with leading biotechnology and microbiology equipment manufacturers. (Source - Access)
  • In April 2024, PixCell Medical, a global provider of innovative point-of-care diagnostic solutions, made a strategic distribution partnership with Medline, Henry Schein, and Thermo Fisher Scientific to expand distribution of its flagship product, the HemoScreen point-of-care Complete Blood Count (CBC) analyzer, across the United States. (Source - PR newswire)
  • In March 2024, Sysmex, a global leader in in vitro diagnostics (IVD) and a manufacturer of medical devices, allied with CellaVision, a medical technology company, to advance hematology solutions. (Source - Select science)

What is the Role of AI in the Hematology Analyzers Market?

In 2025, raised adoption of technological advancements, including AI, ML, and cloud connectivity, with enhanced automation in hematology analyzers and rising movement towards point-of-care testing, is boosting the throughput, minimizing manual intervention, and reducing human error with an increased accuracy level. As a growing cases of blood disorders require major diagnostic accuracy, streamlining workflows, and enabling personalized medicine by coupling with AI-driven tools.

Market Dynamics

Driver

Rising Blood Disorders and the Adoption of Innovations

Blood disorders like anemia, leukemia, and coagulation disorders are fueling growth in the number of cases, with accelerating demand for hematology analyzers across the world. As well as increased research and development activities in sectors such as pharmacogenomics, genetic therapies, and stem cell research, along with significant technological breakthroughs with raised diagnostic accuracy and the development of personalized medicine, are driving the expansion of the hematology analyzers market.

Number of Blood Cancer Patients in US and India in 2024

Restraint

High Expenses and a Shortage of Skilled Personnel

The market is facing emerging challenges, including higher initial spending, especially for advanced models in resource-constrained settings and developing countries. Besides this, along with delayed regulatory approvals for new technologies, limited trained and skilled laboratory personnel to operate and maintain these complex instruments are creating a barrier for effective use and adoption in the market.

Opportunity

Escalating Innovations and the Emergence of Home Healthcare

The hematology analyzers market will have enormous opportunities in the upcoming years, such as innovations in microfluidics, lab-on-a-chip technology, and the integration of AI with accelerated sensitivity, accuracy, and automation properties of these analyzers. Whereas, majorly impacting adoption and utilization of telemedicine and remote patient monitoring are raising development in home healthcare. Also, increasing demand for POC hematology analyzers, especially in emergency departments and clinics, is developing new avenues for market growth.

Segmental Insights

Why did the 5-Part Differential Hematology Analyzers Segment Dominate the Market in 2024?

By product type, the 5-part differential hematology analyzers segment led the global hematology analyzers market, due to growing cases of blood conditions and greater demand for highly accurate and detailed blood cell analysis. Primarily, these analyzers provide detailed information on neutrophils, lymphocytes, monocytes, eosinophils, and basophils for diagnosing and managing different diseases.

However, the 6-part and above/high-end analyzers segment is predicted to grow rapidly, with raised demand for more sophisticated analyzers, which enable rapid, more precise, and automated analysis in the modernized globe. Also, expansion of new hospitals and diagnostic labs, particularly in emerging markets, is in high demand for this testing equipment for oncology and specialized testing.

Shape, PictureBy technology, Which Segment leads the Hematology Analyzers Market in 2024?

The flow cytometry-based analyzers segment held a ~46% share in the market in 2024. The segment possesses advantages like detailed analysis of individual cells, with more specific data about cell types, and other multiple parameters, such as cell size, granularity, and fluorescence intensity, are propelling the overall market and segment expansion.

Shape, PictureBy technology, the artificial intelligence & machine learning integration segment is estimated to show the fastest growth, due to its major benefits, which include increased diagnostic accuracy, automating data analysis, and improving the efficiency of blood analysis. This will result in minimal human intervention with rapid turnaround times and more accurate disease classification. 

How did the Complete Blood Count (CBC) Segment Dominate the Market in 2024?

By application, the complete blood count (CBC) segment dominated nearly 58% share of the global hematology analyzers market in 2024. Increasing geriatric population with major disorders demanding more frequent blood testing, including CBCs, for early detection and management. Along with this, CBC tests are the basis of routine checkups and pre-surgical assessments.

Mainly, the coagulation & platelet studies segment will show rapid growth is driven by cancer and cardiovascular care, in rising cases of cancer and heart conditions. Besides this, across the globe, growing demand for biological drugs and self-administration is supporting pharmaceutical companies to invest in developing advanced drug delivery systems such as dual-chamber prefilled syringes, which need coagulation testing. 

What made the Hospitals Segment lead the Hematology Analyzers Market in 2024?

The hospitals segment was dominant in the market, with a major role of hematology analysis in diagnosing various conditions like infections, anemia, and malignancies, allied with the more cases and the requirement for quick, reliable results within hospitals.

The ambulatory surgical centers & physician offices segment will expand at the fastest CAGR during 2025-2034. The major contributing factors are raised POCT, rising adoption in arthroscopy and joint repair in which hematology testing is necessary, with its inexpensive property for numerous procedures, as compared to hospitals, are appealing to patients and healthcare professionals as the best choice.

Why did the Standalone Hematology Analyzers Segment Hold the Major Share of the Market in 2024?

Shape, PictureBy modality, the standalone hematology analyzers segment dominated the global hematology analyzers market in 2024. The segment is fueled by the growing prevalence of blood disorders, with significant adoption in hospitals and reference labs for their ability to manage a large volume of tests with accuracy and efficiency. 

On the other hand, the integrated systems with immunoassay/chemistry platforms segment will grow fastest due to its comprehensive diagnostic will allow a more holistic view of a patient's health, with more precise diagnoses and treatment plans. As well as the increasing demand for automation and efficiency in clinical laboratories will assist in the expansion of the ultimate segment and market growth.

Regional Insights

Hematology Analyzers Market Share, By Region, 2024 (%)

What made North America dominate the Market in 2024?

North America is dominated hematology analyzers market share by 41% in 2024 by fueling factors, such as high diagnostic volumes, chronic disease screening, and centralized lab chains. Furthermore, the region has been broadly investing in healthcare infrastructure development, especially in clinical laboratories and research institutes, which is driving the demand for advanced hematology testing solutions.

The U.S. Hematology Analyzers Market Trends

In the US, the major expansion of the market is driven by continuous advancements in hematology analyzers, such as the development of highly precise and robust instruments and the integration of AI-based systems, along with research and development activities, including areas like pharmacogenomics, genetic therapies, and stem cell research.

For this market,

  • In February 2025, Foundation Medicine, Inc., a genomics company committed to transforming cancer care, collaborated with Sumitomo Pharma America to accelerate investigational treatment for patients with acute leukemia with NPM1 Mutations or KMT2A rearrangements using the foundationone®heme platform. (Source - Businesswire)
  • In December 2024, BD (Becton, Dickinson and Company), a leading player in medical technology, and Babson Diagnostics, a science-first health care technology company, announced their expansion of fingertip blood collection and testing technologies for use by U.S. health systems. (Source - BD)

The Canada Hematology Analyzers Market Trends

In Canada, the market is fueled by raised awareness amo    ng healthcare professionals about the benefits of using hematology analyzers for prior diagnosis and monitoring of many conditions, contributing to their adoption. Although, Canadian government is encouraging healthcare approachability and infrastructure development is playing a major role in the market growth.

Accelerating Healthcare Infrastructure in Developing Countries is Driving Asia Pacific

In the upcoming years (2025-2034), Asia Pacific is predicted to grow at the fastest CAGR, as developing countries like India, China, and Southeast Asia are widely investing in healthcare infrastructure. These developed infrastructures will demand an advanced healthcare system with sophisticated equipment, including hematology analyzers. However, developing incidences of anemia, thalassemia, and blood cancers in ASAP are an important driver for the respective market growth.

The India Hematology Analyzers Market Trends

India is experiencing rapid growth due to boosting cases of anemia, thalassemia, and blood cancers highly particularly in rural areas are demanding advanced technologies like analyzers to accelerate the diagnosis. Whereas, government initiatives like Ayushman Bharat are enhancing awareness about blood diseases and raising demand for diagnostic tools.

For instance,

  • In May 2025, Sattva Group, one of Bengaluru’s leading real estate developers, has partnered with the esteemed Sankalp India Foundation to introduce a series of blood donation drives around its IT parks in the city. (Source - The hans India)

The China Hematology Analyzers Market Trends

The market in China is propelled by growing susceptibility to hematological diseases due to a growing geriatric population, along with increased expenditure on the healthcare system and government programs promoting regular blood testing and improved healthcare access.

For instance,

  • In May 2025, Fangzhou Inc., an emerging player in Internet healthcare solutions, launched Otsuka Pharmaceutical's third-generation tyrosine kinase inhibitor (TKI) Iclusig® (ponatinib) through its online platform employed in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). (Source - morningstar)

Major Technological Advancements and Preference for POCT are Driving Europe

Europe in the hematology analyzers market is facing significant growth, influenced by growing healthcare investments with innovations in technologies, such as the integration of flow cytometry, artificial intelligence, and automation, and increasing preference for point-of-care (POC) testing in outpatient settings, remote areas, and emergencies are boosting demand for easily accessible and consumer-friendly hematology analyzers.

For this market,

  • In June 2025, Avanzanite Bioscience B.V., a rapidly developing commercial-stage specialty pharmaceutical company, announced an exclusive agreement with Agios Pharmaceuticals Inc., a Boston-based biotech company, to adopt rare disease medicines to patients across Europe. (Source - Afp)

The UK Hematology Analyzers Market Trends

The UK’s market is experiencing growth with combined influential factors like raised adoption of early diagnosis, technological developments with automation, and majorly growing awareness about rising blood conditions like anemia, leukemia, and thalassemia.

For instance,

In July 2025, Manchester researcher awarded £300k as Blood Cancer UK launched £70 million strategy. (Source - Bloodcancer)

The Germany Hematology Analyzers Market Trends

In Germany, innovations in instruments and systems, like electronic morphology systems, ESR analyzers, and slide-makers with advanced features, are achieving traction, with emphasis on translational research, personalized medicine, and drug development is fueling investments in advanced hematology analyzers within the research community. 

For this market, 

  • In July 2024, Biogen, Beckman Coulter, and Fujirebio collaborated to develop blood-based biomarkers and test for tau pathology in Alzheimer’s disease. (Source - Biogen)

Top Companies in the Hematology Analyzers Market

Hematology Analyzers Market Companies

  • Sysmex Corporation
  • Beckman Coulter (Danaher Corporation)
  • Abbott Laboratories
  • Siemens Healthineers
  • Horiba Ltd.
  • Mindray Medical International Limited
  • Bio-Rad Laboratories, Inc.
  • Roche Diagnostics
  • Boule Diagnostics AB 
  • Diatron MI Zrt. (Stratec Biomedical)
  • Nihon Kohden Corporation 
  • Ortho Clinical Diagnostics 
  • Drucker Diagnostics
  • PixCell Medical Technologies 
  • Dymind Biotechnology Co., Ltd.
  • Heska Corporation (veterinary segment)
  • Agappe Diagnostics
  • Dirui Industrial Co., Ltd.
  • Erba Mannheim (Transasia Bio-Medicals Ltd.) 
  • Thermo Fisher Scientific (hematology reagents & kits) 

Latest Announcements by Industry Leaders

  • In May 2025, MCRI, a flagship member of the Melbourne Biomedical Precinct and the Melbourne arm of the international research consortium, the Novo Nordisk Foundation Center for Stem Cell Medicines (reNEW), announced a major agreement with Retro Biosciences to advance a blood stem cell innovation worth $35 million. Retro Biosciences Co-founder and CEO Joe Betts-LaCroix stated that they have dreamed about stem cells field conversion to pluripotent stem cells to blood stem cells to maintain an individual’s health. (Source - The pharmaletter)
  • In March 2025, Sysmex America, Inc., a leading diagnostic solutions company, announced the expansion of its 3-part differential automated hematology analyzer line with the XQ-320™ for reliable and accurate CBC testing. Dan Zortman, CEO of Sysmex America, commented that this will allow minimum volume labs and hospitals a better choice to deliver high-quality results with a shorter turnaround time. (Source - PR newswire)

Recent Developments in the Hematology Analyzers Market

  • In April 2025, AbbVie, a global biopharmaceutical company, launched Venetoclax in India to treat both Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL). (Source - Expresshealthcare)
  • In March 2025, Novo Nordisk launched new therapies called  Ozempic and Wegovy in blood and growth disorders after success in diabetes and obesity. (Source - Financial express)
  • In June 2024, HORIBA, a global leader in analytical and measurement technology, accelerated its compact hematology instrument range with the unveiling of new models with erythrocyte sedimentation rate (ESR) on board. (Source - Select science)

Segments Covered in the Report

By Product Type 

  • 3-Part Differential Hematology Analyzers 
  • 5-Part Differential Hematology Analyzers
  • 6-Part and Above / High-End Analyzers
  • Point-of-Care Hematology Analyzers
  • Hematology Reagents & Consumables 

By Technology 

  • Impedance-Based Analyzers 
  • Flow Cytometry-Based Analyzers
  • Digital Imaging Technology 
  • Artificial Intelligence & Machine Learning Integration
  • Microfluidics (for miniaturized & portable analyzers) Shape, Picture 

By Application 

  • Complete Blood Count (CBC)
  • Hemoglobin & Hematocrit Analysis
  • Reticulocyte Count 
  • White Cell Differential Count 
  • Coagulation & Platelet Studies 

By End User 

  • Hospitals
  • Clinical Diagnostic Laboratories 
  • Research & Academic Institutes
  • Blood Banks 
  • Ambulatory Surgical Centers & Physician Offices

By Modality

  • Standalone Hematology Analyzers 
  • Integrated Systems with Immunoassay/Chemistry Platforms

By Region 

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Thailand
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
  • Last Updated: 10 July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

Meet the Team

Kesiya Chacko is an accomplished market research professional with over 4+ years of experience in the healthcare industry, known for delivering actionable insights and strategic analysis that empower healthcare organizations.

Learn more about Kesiya Chacko

Aditi Shivarkar, with over 14 years of experience in consumer goods, leads research at Towards Consumer Goods, ensuring precise, actionable insights on trends, consumer preferences, and sustainable packaging for businesses.

Learn more about Aditi Shivarkar

Related Reports

FAQ's

The hematology analyzers market is projected to reach USD 7.28 billion by 2034, growing at a CAGR of 5.97% from 2024 to 2034.

North America is currently leading the hematology analyzers market due to high diagnostic volumes, chronic disease screening, and centralized lab chains.

The hematology analyzers market includes 6 segments, such as by product type, by technology, by application, by end user, by modality, and by region etc.

Some key players include Sysmex Corporation, Beckman Coulter (Danaher Corporation), Abbott Laboratories, Siemens Healthineers, and Horiba Ltd. 

Key trends include rising demand for advanced diagnostic equipment and POCT, growth in investments in healthcare infrastructure, and innovation in automated and AI-driven technologies in hematology.

A hematology analyzer provides information regarding CBC, differential WBC count, red blood cell indices, and platelet parameters.

Hematology analyzer has some common faults like counting small hole blockage, aspiration needle blockage, pump tube aging, filter is not smooth, directional valve failure, solenoid valve blockage, waste liquid cup accumulation, insufficient reagent volume, and sample volume shortage, and so on.

The main purpose of hematology includes blood and bone marrow cells. Also, hematological tests support to diagnosis of anemia, infection, hemophilia, blood-clotting disorders, and leukemia.

NIH.GOV, CDC.GOV, US FDA. GOV, PIB.GOV, MoHFW, ICMR, ISHBT, ASH.GOV, ACTREC.GOV